The company has met its goal of enrolling 50 subjects by the end of January 2021.
EpiTech is proud to welcome Hadassah, Rabin and HaEmek Medical Centers as enrolling sites in pilot study
Based on the Excellent results achieved during the 1st clinical trial, today EpiTech officially launched its 2nd clinical trial, a 40 patient, multi center, double masked, randomized controlled study.
Pre-clinical results of EpiTech’s Ocular Neuromagnetic Stimulation System published by Ocular Surface
“Repetitive magnetic stimulation protects corneal epithelium in a rabbit model of short-term exposure keratopathy” is the headline for the Ocular Surface’s most recent review of EpiTech’s pre-clinical success.
During 2019 EpiTech concluded its 1st human clinical trial, treating a total of 29 moderate to severe dry eye disease patients in a multicenter study in 3 sites.
EpiTech’s Ocular Magnetic Neurostimulation reduced corneal staining and improved quality of life in patients with dry eye disease.
Results from EpiTech’s First in Human Trial presented by Prof. David Zadok at the American Society of Cataract and Refractive Surgery (ASCRS) Conference in San Diego
At the 2019 ASCRS, Professor Zadok presented the initial results from EpiTech’s 1st pilot study treating a total of 15 patients.
The ongoing pilot study (N=30) has enrolled 15 moderates to severe dry eye patients in an open label, single arm study.
Dr. Bar shares exciting clinical results based on the first five patients enrolled and treated in EpiTech’s clinical study